Navellier & Associates’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$313K Sell
2,600
-86
-3% -$9.93K 0.03% 277
2025
Q4
$283K Sell
2,686
-5,707
-68% -$536K 0.03% 283
2025
Q3
$704K Buy
8,393
+244
+3% +$20.1K 0.07% 216
2025
Q2
$645K Hold
8,149
0.08% 185
2025
Q1
$675K Sell
8,149
-6,604
-45% -$617K 0.09% 175
2024
Q4
$1.47M Buy
14,753
+2,035
+16% +$210K 0.18% 123
2024
Q3
$1.44M Sell
12,718
-2,761
-18% -$328K 0.2% 109
2024
Q2
$1.92M Sell
15,479
-86
-0.6% -$11.1K 0.23% 102
2024
Q1
$2.05M Sell
15,565
-921
-6% -$114K 0.25% 97
2023
Q4
$1.8M Buy
16,486
+2,756
+20% +$286K 0.27% 97
2023
Q3
$1.41M Buy
13,730
+3,994
+41% +$430K 0.24% 108
2023
Q2
$1.12M Buy
9,736
+382
+4% +$43.4K 0.22% 112
2023
Q1
$995K Sell
9,354
-1,089
-10% -$118K 0.21% 107
2022
Q4
$1.16M Buy
10,443
+516
+5% +$52.7K 0.24% 99
2022
Q3
$855K Sell
9,927
-470
-5% -$42K 0.19% 113
2022
Q2
$948K Buy
10,397
+99
+1% +$8.78K 0.2% 114
2022
Q1
$845K Sell
10,298
-127
-1% -$10K 0.14% 133
2021
Q4
$799K Sell
10,425
-562
-5% -$44.8K 0.12% 155
2021
Q3
$825K Sell
10,987
-536
-5% -$40.8K 0.12% 153
2021
Q2
$896K Sell
11,523
-734
-6% -$54.6K 0.14% 148
2021
Q1
$902K Sell
12,257
-780
-6% -$57.5K 0.16% 127
2020
Q4
$1.02M Sell
13,037
-448
-3% -$34.3K 0.18% 114
2020
Q3
$1.07M Sell
13,485
-1,331
-9% -$104K 0.23% 100
2020
Q2
$1.09M Buy
14,816
+10,926
+281% +$823K 0.26% 93
2020
Q1
$286K Sell
3,890
-5,293
-58% -$416K 0.07% 179
2019
Q4
$797K Buy
9,183
+262
+3% +$21.5K 0.13% 153
2019
Q3
$717K Sell
8,921
-97
-1% -$7.77K 0.12% 159
2019
Q2
$722K Sell
9,018
-422
-4% -$32.3K 0.11% 155
2019
Q1
$749K Sell
9,440
-308
-3% -$23K 0.12% 140
2018
Q4
$711K Buy
9,748
+4,925
+102% +$348K 0.12% 125
2018
Q3
$326K Sell
4,823
-7,859
-62% -$501K 0.04% 228
2018
Q2
$735K Sell
12,682
-1,152
-8% -$65K 0.1% 165
2018
Q1
$719K Sell
13,834
-2,279
-14% -$123K 0.11% 156
2017
Q4
$865K Sell
16,113
-33,117
-67% -$1.84M 0.16% 142
2017
Q3
$3.01M Sell
49,230
-10,811
-18% -$655K 0.58% 51
2017
Q2
$3.67M Sell
60,041
-3,468
-5% -$211K 0.55% 54
2017
Q1
$3.85M Sell
63,509
-1,781
-3% -$108K 0.56% 72
2016
Q4
$3.67M Sell
65,290
-5,664
-8% -$331K 0.61% 70
2016
Q3
$4.22M Sell
70,954
-2,408
-3% -$141K 0.6% 61
2016
Q2
$4.03M Buy
73,362
+2,772
+4% +$148K 0.6% 53
2016
Q1
$3.56M Buy
70,590
+3,033
+4% +$149K 0.46% 50
2015
Q4
$3.4M Buy
67,557
+257
+0.4% +$13K 0.37% 49
2015
Q3
$3.17M Buy
67,300
+1,474
+2% +$78.3K 0.32% 50
2015
Q2
$3.58M Buy
65,826
+9,118
+16% +$511K 0.31% 42
2015
Q1
$3.11M Buy
56,708
+2,837
+5% +$161K 0.28% 47
2014
Q4
$2.92M Buy
53,871
+5,274
+11% +$294K 0.15% 42
2014
Q3
$2.75M Buy
48,597
+3,249
+7% +$182K 0.14% 50
2014
Q2
$2.5M Buy
45,348
+19,370
+75% +$1.06M 0.11% 56
2014
Q1
$1.41M Buy
25,978
+7,094
+38% +$367K 0.07% 76
2013
Q4
$902K Buy
18,884
+2,888
+18% +$132K 0.04% 110
2013
Q3
$727K Buy
15,996
+10,532
+193% +$481K 0.02% 148
2013
Q2
$242K Buy
+5,464
New +$244K 0.01% 241

Other funds holding MRK

Navellier & Associates's MRK Position: Q1 2026 in Review

Navellier & Associates reduced its Merck (MRK) stake by 3.2% in Q1 2026, selling an estimated $9.93K and leaving 2,600 shares worth $313K. The position accounts for 0.03% of the portfolio, ranked #277.

Navellier & Associates first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.22M in Q3 2016. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Navellier & Associates held 2,600 shares of Merck worth $313K as of Q1 2026.
  • Navellier & Associates sold 86 Merck shares in Q1 2026, an estimated $9.93K.
  • Merck made up 0.03% of Navellier & Associates's portfolio in Q1 2026, its #277 holding.
  • Navellier & Associates first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
  • Navellier & Associates's Merck position peaked at $4.22M in Q3 2016.
  • 3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Navellier & Associates's 13F filing for Q1 2026, filed 7 May 2026.